Asymmetric gpr84 antagonist and use thereof

A compound represented by general formula (I), or an enantiomer, diastereoisomer, racemate, or a pharmaceutically acceptable salt thereof,

• wherein Y is O or S;
• Z is H, or an ion of the following metals:
• Li, Na, K, Ca, Mg, Cu, Fe, Zn, Al, Mn, or a conjugate acid of the following bases:
• NH3, arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, histidine, hydroxycobalamin, isopropylamine, lysine, methyl glucosamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, trometamol, imidazole;
• L1 is none, O, S, —CH═CH—, —CO—, —C(═CH2)—, substituted or unsubstituted C1-C6 alkylene, —NH—, —N(C1-C4 alkyl)—, C3-C6 cycloalkyl or C3-C6 heterocycloalkyl, and the substitution means that there is one or more substituents selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halogen, and hydroxyl;
• L2 is none, CH;
• ring A and ring B are each independently a C6-C10 aromatic ring, a C3-C10 cycloalkane ring, a C3-C10 heterocycloalkane ring, or a C3-C10 heteroaryl ring;
• n1 and n2 are each independently 0, 1, 2, 3 or 4;
• R1 and R2 are each independently —OH, —SH, —NH2, F, Cl, Br, I, substituted or unsubstituted —CrH2r—L7—CsH2s+1, —CrH2r—N(CtH2t+1)—CsH2s+1, substituted or unsubstituted C1-C6 alkyl, the above substitution means that there is one or more substituents selected from the group consisting of halogen, hydroxyl, amino, —COOC1-C6 alkyl, —COOH;
• each L7 is independently O, S, NH;
• each r is independently 0, 1, 2, 3, 4, 5 or 6;
• each s is independently 0, 1, 2, 3, 4, 5 or 6;
• and each t is independently 1, 2, 3, 4, 5, or 6;
• L3 and L4 are each independently O, none, —O(C1-C10 alkylene)—, —O(C1-C10 alkylene)NH—, —O(C1-C10 alkylene)O—, —CONH—, —OCO—, —NH—, —NHCOO—, —N(C1-C6 alkyl)—, or C1-C10 alkylene;
• R3 is H, OH, NH2, SH, —COOH, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C2-C10 alkenyl, substituted or unsubstituted C2-C10 alkynyl, substituted or unsubstituted 3-12 membered cycloalkane ring, substituted or unsubstituted C6-C14 aromatic ring, substituted or unsubstituted amino, substituted or unsubstituted 4-10 membered heterocycloalkane ring, substituted or unsubstituted 4-10 membered heteroaromatic ring, cholic acid, lithocholic acid, deoxycholic acid, isolithocholic acid, isodeoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, α-muricholic acid, β-muricholic acid, γ-muricholic acid, ω-muricholic acid;
• and the above substitution means that there is 1, 2, 3, 4, 5 or 6 substituents selected from the following group consisting of amino, C1-C10 alkyl, halogen, C6-C10 aromatic ring, C1-C6 alkoxy, 3-12 membered cycloalkane ring, —O—CpH2p—O—CqH2q+1, nitro, oxo (═O), hydroxyl, carboxyl, —C(O)OC1-C6 alkyl, —O—C6-C10 aromatic ring, —NH—(4-10 membered heteroaromatic ring), —NH—(4-10 membered heteroaromatic ring)—CONH2;
• wherein each p is independently 1, 2, 3, 4, 5 or 6, and each q is independently 1, 2, 3, 4, 5 or 6;
• each independently represents a single or double bond.